Neuromuscular Blockade — Reversal of Neuromuscular Blockade and Perioperative Arrhythmias
Citation(s)
Carron M, Zarantonello F, Tellaroli P, Ori C Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016 Dec;35:1-12. doi: 10.1016/j.jclinane.2016.
Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009 Oct;26(10):874-84. doi: 10.1097/EJA.0b013e32832c605b.
Hristovska AM, Duch P, Allingstrup M, Afshari A The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2
Kizilay D, Dal D, Saracoglu KT, Eti Z, Gogus FY Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. J Clin Anesth. 2016 Feb;28:30-5. doi: 10.1016/j.jclinane.2015.08.002. Epub 2015 Nov 11.
Lorentz MN, Vianna BS Cardiac dysrhythmias and anesthesia. Rev Bras Anestesiol. 2011 Nov-Dec;61(6):798-813. doi: 10.1016/S0034-7094(11)70090-3. Review. English, Multiple languages.
Staikou C, Stamelos M, Stavroulakis E Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity. Br J Anaesth. 2014 Feb;112(2):217-30. doi: 10.1093/bja/aet412. Epub 2013 Dec 3. Review.
Yamashita Y, Takasusuki T, Kimura Y, Komatsuzaki M, Yamaguchi S Effects of Neostigmine and Sugammadex for Reversal of Neuromuscular Blockade on QT Dispersion Under Propofol Anesthesia: A Randomized Controlled Trial. Cardiol Ther. 2018 Dec;7(2):163-172. d
Influence of the Neuromuscular Blockade and Its Reversal on Perioperative Arrhythmias
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
